Takeda Pharmaceutical, a major Japanese pharmaceutical company, has made a $62 billion offer to acquire Shire, an Ireland-based leader in rare disease treatments. This proposal, Takeda’s fourth attempt to purchase Shire, comes after Shire had previously rejected three offers, citing undervaluation of its business and future growth prospects. Escalation in Acquisition Offers The latest bid […]
Procter & Gamble (P&G), a leading US consumer goods company, has finalized a deal to acquire the consumer health business of German pharmaceutical company Merck for approximately €3.4 billion ($4.2 billion). This all-cash transaction marks a significant expansion of P&G’s consumer health division by incorporating a range of over-the-counter (OTC) products from Merck. Expanding P&G’s […]
In a strategic move to expand its global presence, French pharmaceutical giant Servier Laboratories has announced a $2.4 billion all-cash acquisition of the oncology business from Irish biotech company Shire. This significant transaction positions Servier to substantially increase its oncology portfolio and establish a direct commercial presence in the United States, the world’s largest biopharmaceutical […]
Significant Investment in Vaccine Production: French pharmaceutical giant Sanofi has announced plans to invest CAD 500 million (approximately $396.3 million) to construct a new vaccine manufacturing facility at its Canadian headquarters, Sanofi Pasteur, in Toronto. This development is aimed at bolstering the company’s operational capabilities in Canada and reaffirming its commitment to advancing global public […]
In a significant move to expand its rare disease drug portfolio, U.S.-based Alexion Pharmaceuticals has announced an all-cash acquisition of Swedish pharmaceutical company Wilson Therapeutics for SEK7.1 billion ($855 million). This strategic acquisition is set to significantly bolster Alexion’s offerings in the rare disease sector, particularly in treating Wilson disease, a rare copper-mediated disorder. Details […]
GlaxoSmithKline (GSK), a leading British pharmaceutical company, has entered into a significant agreement with Orchard Therapeutics, transferring its rare disease gene therapy drugs in exchange for a 19.9% equity stake and a seat on Orchard’s board. This move is part of GSK’s strategic initiative to refine its focus on core areas such as respiratory, HIV/infectious […]
Novartis, a Swiss pharmaceutical giant, has confirmed a substantial acquisition of AveXis, a US-based gene therapy company, for a total of $8.7 billion. This strategic move is set to enhance Novartis’s capabilities in gene therapy and neuroscience, particularly in the treatment of spinal muscular atrophy (SMA). Strategic Acquisition in Pharma Under the agreement, Novartis will […]
In a major strategic shift, GlaxoSmithKline (GSK) has finalized an agreement to acquire Novartis’ 36.5% stake in their consumer healthcare joint venture for $13 billion. This move comes shortly after GSK withdrew from a $20 billion bid to purchase Pfizer’s consumer healthcare business, indicating a focused realignment of GSK’s investment towards owning 100% of its […]
Pfizer’s $20 Billion Sale Stalls: In a significant turn of events in the pharmaceutical industry, both Reckitt Benckiser and GlaxoSmithKline (GSK) have decided to withdraw from acquisition talks with Pfizer regarding its consumer healthcare business. This decision marks a setback for Pfizer’s plans to offload this segment, valued at approximately $20 billion. Overview of Pfizer’s […]
Lundbeck, a leading Danish pharmaceutical company, has announced its acquisition of Prexton Therapeutics, a Swiss firm specializing in the development of drugs for Parkinson’s disease, in a deal valued at approximately $1.1 billion. This strategic acquisition is set to enhance Lundbeck’s capabilities in neurology, particularly in the treatment of Parkinson’s disease. Financial Structure of the […]